Skip to main content

Table 6 Predictors of pneumonia in RA patients by the Cox-hazard model (Multivariate analysis)

From: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

 

Hazard ratio

P value

95% CI

Demographics

 Age (years)

1.039

0.068

0.997–1.083

 Gender, male

0.580

0.317

0.200–1.686

 Smoking history

1.247

0.670

0.452–3.443

Laboratory data

 CRP (mg/dl)

1.384

0.268

0.779–2.459

 Serum albumin (g/dl)

0.917

0.877

0.305–2.758

 Serum creatinine (mg/dl)

1.550

0.366

0.599–4.005

RA characteristics

 RA duration (years)

1.010

0.582

0.974–1.048

 HAQ

1.202

0.506

0.699–2.067

 DAS28 (CRP)

1.026

0.936

0.545–1.933

 SDAI

0.945

0.845

0.534–1.670

 CDAI

0.944

0.851

0.517–1.723

Comorbidity

 Cardiovascular disease

1.138

0.749

0.515–2.518

 Metabolic disease

1.283

0.542

0.576–2.856

 CKD

1.402

0.689

0.268–7.344

 Autoimmune disease

0.468

0.494

0.053–4.137

 Interstitial pneumonia

3.611

0.003

1.553–8.399

PPSV23 vaccination

0.849

0.656

0.414–1.743

Treatment

 PSL

1.081

0.846

0.492–2.375

 MTX

1.431

0.390

0.632–3.240

 TAC

0.712

0.552

0.232–2.182

 Biologics

0.664

0.307

0.302–1.458

  1. PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein, RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, CKD chronic kidney disease, PSL prednisolone, MTX methotrexate, TAC tacrolimus, CI confidence interval
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us